Glimepiride/pioglitazone

An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC₅₀ = 8 nM) shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine

An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC₅₀ = 8 nM) shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine

An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC₅₀ = 8 nM) shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine

PPC-NB is a glutathione cleavable linker used for the antibody-drug conjugate (ADC)Form:OilIC50&amp: Target:Disulfide Cleavable.

PGB2 is a non-enzymatic dehydration product resulting from the treatment of PGE2 or PGA2 with strong base. It has weak agonist activity on TP receptors and can increase pulmonary blood pressure in the rabbit at relatively high doses (5 &microg/kg).

PGD1 is the theoretical D-series metabolite of DGLA, but to date it has not been isolated as a natural product. It is an inhibitor of ADP-induced platelet aggregation in humans with an IC50 value of 320 ng/ml, about 1/10 as potent as PGD2.

PGD2 dopamine is a conjugate of the neurotransmitter dopamine and PGD2. It can be used to study the biological function of PGD2 in the brain and periphery.

PGD2 dopamine is a conjugate of the neurotransmitter dopamine and PGD2. It can be used to study the biological function of PGD2 in the brain and periphery.

PGD2 dopamine is a conjugate of the neurotransmitter dopamine and PGD2. It can be used to study the biological function of PGD2 in the brain and periphery.

An internal standard for the quantification of PGD2 dopamine by GC- or LC-MS.

PGD3 is produced by the metabolism of EPA via the COX pathway. It is equipotent to PGD2 in decreasing systemic blood pressure in rats and in decreasing intraocular pressure in rabbits.

PGE1 is the theoretical COX metabolite of DGLA, but it is virtually undetectable in the plasma of normal humans or other animals. Its pharmacology includes vasodilation, hypotension, and anti-platelet activities.